Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Clearway Health, a specialty pharmacy accelerator partnering with hospitals and health systems, has pioneered a model to support hospitals in...
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — ...
(MENAFN - GlobeNewsWire - Nasdaq) - NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 - - NDA is supported by data from successful Phase ... ...
Commercial-stage biopharma company, Hutchmed, has good news for adults with primary immune thrombocytopenia (ITP).